drugset / Trial / NCT00705978

Creon 40,000 for Treatment of PEI (Pancreatic Exocrine Insufficiency) Due to Chronic Pancreatitis

NCT00705978

Phase 3 Completed 62 enrolled Abbott Products Data Map GmbH · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will provide efficacy data for Creon 40,000 in CP subjects as well as long-term safety data. During the long-term treatment with Creon 40,000 nutritional parameters will be assessed and correlated with CFA.

Timeline

Start
2008-06
Primary completion
2010-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Pancrelipase Protein / enzyme biologic 40000 iu